Extracellular Vesicle Profiling and Their Use as Potential Disease Specific Biomarker by Henrike Julich et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MINI REVIEW ARTICLE
published: 01 September 2014
doi: 10.3389/fimmu.2014.00413
Extracellular vesicle profiling and their use as potential
disease specific biomarker
Henrike Julich1, ArnulfWillms2,Veronika Lukacs-Kornek 1 and Miroslaw Kornek 1,2*
1 Department of Medicine II, Saarland University Medical Center, Homburg, Germany
2 Department of General, Visceral and Thoracic Surgery, German Armed Forces Central Hospital, Koblenz, Germany
Edited by:
Martin Johannes Hoogduijn, Erasmus
Medical Center, Netherlands
Reviewed by:
Luuk Hilbrands, Radboud University
Nijmegen Medical Centre,
Netherlands
Estrella Mariel Levy, Consejo Nacional
de Investigaciones Cientificas y
Tecnicas, Argentina
*Correspondence:
Miroslaw Kornek, Department of
Medicine II, Saarland University
Medical Center, Kirrbergerstr. 100,
Homburg 66421, Germany
e-mail: miroslawkornek@web.de
Cell-derived vesicles in particular extracellular vesicles (EVs) such as microparticles (MPs)
and microvesicles besides exosomes are raising more and more attention as a novel and
unique approach to detect diseases. It has recently become apparent that disease specific
MP signatures or profiles might be beneficial to differentiate chronic liver diseases such
as non-alcoholic fatty liver disease and chronic hepatitis C, to monitor their progression or
possibly to assess treatment outcome. Therefore EVs might serve as a novel inexpensive
and minimally invasive method to screen risk patients for the outbreak of a disease even
before the initial symptoms, to follow up treatment complications and disease relapse.
The purpose of the current review is to summarize already published EVs signatures for a
limited number of exemplary diseases and to discuss their possible impact. Additionally, it
will be discussed if the combination of EV profiling and miRNA profiling could be a future
joint tool for the purpose of detecting cancer and from far larger interest to ultimately dis-
tinguish among various tumor entities. EVs might increase the chance of early detection
of chronic diseases or cancers especially if applied as part of yearly health screenings in
the future.
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INTRODUCTION
Extracellular vesicles (EVs) were first time described as an
unwanted contamination of an experimental preparation of
platelets and eventually called “platelets dust” by Wolf (1).
Advanced methodologies such as fluorescence activated cell sort-
ing (FACS) enabled their detailed characterization during the
last decade. The relatively novel term EVs includes exosomes
and activation- or apoptosis-induced microparticles/microvesicles
(MPs/MVs). MPs/MVs are 100–1000 nm in diameter, sometimes
referred to ectosomes and representing a novel route of horizontal
communication between cells within the living organism through
various body fluids. In contrast, exosomes are smaller in size,
<100 nm, and opposite to MPs they are formed and stored within
the cell before their release (2–4). MPs/MVs are generated through
a process of cell membrane shedding called ectocytosis that is
associated with the activation of the complement system C5b-9
complex or influx of Ca2+. Moreover, this process includes specific
sorting of membrane proteins into the shedded membrane frac-
tion of MPs/MVs and phosphatidylserine exposure during cellular
activation or early apoptosis (4, 5). It seems that the activation of
the parental cell might be the major release trigger of MPs in vivo,
since 80% of the CD8+ T cell-derived MPs were positive for the T-
cell activation marker CD25 (6). MPs/MVs seem to resemble their
parental cells and share with them many characteristics, such as
surface receptors, integral membrane proteins, as well as cytosolic
proteins, some mRNAs, and even miRNAs (7–11). Above features
make these vesicles very attractive to use as novel minimal invasive
biomarkers (12, 13).
Many recent reviews summarized and discussed in depth their
differences, how to use them as putative biomarkers, their under-
lying unique release mechanisms, and their impact on cell–cell
communication (3, 6, 13–16). The purpose of this review is not
trying to go one better, but rather to discuss useful MP/MV sur-
face biomarkers highly specific for a selected panel of diseases.
Surface markers of MPs are especially relevant, since flow cytom-
etry has become the standard method of choice for characterizing
and quantifying MPs/MVs and their specific subpopulations (12,
17–20).
Extracellular vesicles can interact with their microenvironment
in vitro and in vivo, as shown for many examples of EV–cell inter-
actions that affected transiently the recipient cells. These changes
on the recipient cells manifested as gain of function, as rescue of
function, or as enhancing of function (4, 7, 8). Despite of these
above effects on the microenvironment, EVs were and are utilized
to detect pathophysiological changes and abnormalities in dis-
eases under experimental conditions in plasma-, serum-, or other
body fluids (12, 17, 19, 21, 22). Some publications quantified plain
numbers of MPs/MVs under disease conditions vs. healthy con-
trols (23, 24), whereas others determined a limited number of
distinct MP/MV populations (<3) (18, 20–22, 25, 26). Because
of the limited numbers of investigated MP/MV populations, the
studies likely missed some interesting MP/MV populations that
could be key for the particular disease. A better approach could be
a comprehensive MP/MV based profile that could give the chance
to discover other disease key players as reflected in the types and
numbers of their associated MP/MV populations.
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Additionally, among these early studies with a limited number
of MP/MV populations, few groups acquired plain numbers of
individual MP populations, using flow cytometry surface staining
with or without Annexin V as a general MP/MV marker (25, 27).
More importantly, the isolation protocol of these vesicles shows
great differences from study to study. Thus, it might be difficult to
assess the impact of these older data sets and to compare it in a
meaningful way.
However, a new trend emerged to look for a wider panel
of investigated MP/MV populations, pinpointing disease char-
acteristics and providing evidence which MP/MV parental cell
populations might play a role in disease outbreak and progres-
sion. Recently, MP based disease profiles of shared MP populations
were provided for several human disorders such as atherosclero-
sis, arthritis, hepatitis C infection, non-alcoholic fatty liver disease
(NAFLD), and malaria. In these studies, the authors have quan-
tified several disease related and specific MP populations such as
CD3+, CD4+, CD8+, CD11b+, CD14+, CD15+, CD20+, CD41+,
and CD105+ MPs out of the heterogenic MP pool present within
the circulation (12, 17, 19, 28, 29). Associated but not yet standard-
ized MP/MV disease profiles consisting of individual selections of
MP/MV surface marker that form a unique panel of EV surface
antigens for each indicated disease are summarized in Table 1.
Based on the existing MP/MV profiling data it seems that specific
MP/MV marker combinations and their percentages as measured
by FACS could be unique for each disease despite that several sin-
gle markers appear to be associated with multiple diseases (such
as CD3, CD4, and CD14, Table 1). Thus, the emphasis lies on the
combination of MP/MV markers and their disease specific changes
in these MP/MV populations that will determine specificity. Such
MP/MV analyses should be further optimized and pursued for
covering more disease-marker combinations as seen exemplarily
in case of two gastrointestinal diseases (12).
Upcoming sophisticated MP/MV based disease profile regis-
ters, based on standardized isolation and quantifications protocols,
might give the upcoming opportunity to detect in a minimal inva-
sive manner a wide variety of diseases using a single blood dona-
tion. In fact, one MP/MV surface marker selection (CD4, CD8,
CD14, CD15, CD41, and iNKT) was able to discriminate between
two chronic liver diseases (hepatitis C infection and NAFLD) and
the corresponding healthy cohort. Thus, some disease parameters
as serum ALT and histology were well reflected and correlated with
the selected MP populations. MPs could in these cases be espe-
cially practical since histology based on liver biopsy, a tarnished
gold standard, have high sampling variability as discussed by the
authors (12). These data support the assumption of the under-
lying potential of monitoring and profiling EVs in future clinical
applications.
Another and an even more doable application might be screen-
ing treatment response and outcome by EV profiling. Ideal would
be a normalization of the EV disease profile toward an EV profile
of healthy subjects during a positive treatment response separating
responders from non-responders. Additionally, still speculative, a
negative treatment response mirrored by an unchanged EV pro-
file would give the chance to re-review treatment strategy. In
accordance with these hypotheses, Shao and colleagues showed
that MV protein typing, not EV profiling by surface markers,
was successfully used as a predictive metric of treatment-induced
changes (30). Nevertheless, how EVs will be characterized, if by
their content or by their surface markers (Figure 1), EV isolation,
their identification, and quantification must be simplified and
standardized. Recently, a first step has been done toward simplify-
ing MPs isolation by using Miltenyi Annexin V beads to capture
MPs in body fluids recovering them in equal numbers as done
previously by differential ultracentrifugation (31).
EVs DIAGNOSTIC POTENTIAL AND LIMITATION IN CANCER
EV-based cancer screening provides a huge potential in vari-
ous applications, especially differentiation among cancer entities,
via using just a blood sample. Several experimental studies were
carried out to detect cancer traces by tumor derived EVs; as exo-
somes or MPs/MVs. In vitro the release of tumor derived EVs
showed impact on the tumor escape (32) angiogenesis (33) and
tumor invasiveness (34) indicating that tumor EVs might help
to prime the formation of the metastatic niche as reviewed by
D’Souza-Schorey and Clancy (35, 36).
Up to date, only a very limited number of surface markers
were explored in vivo on tumor derived EVs. Some publica-
tions outlined that in cancer patients the EV load as seen in
plasma or serum samples was elevated (23, 24, 37–39). During
the years, some EV surface tumor markers have been identified
under defined experimental conditions (37, 40). Elevated lev-
els of CD95L expressing MVs have been found to be associated
with oral squamous cell carcinoma (OSCC). However, CD95L
expressing MVs have also been associated with pregnancy, pin-
pointing that the use of single surface markers is not sufficient
to associate MVs with specific diseases (41, 42). In 2008, a hepa-
tocellular carcinoma (HCC) pilot-study was published, showing
that the levels of endothelial (CD31+/CD42-) and hepatocyte
(HepPar) derived MPs in HCC liver transplant patients were
altered after surgery and correlated with the clinical outcome
(37). In vitro, the approach to differentiate between prostate and
breast cancer cell lines based on their MV signature consisting
of more than 10 surface markers, unfortunately, did not result
in a clear separation of the above tumor entities (43). As shown
for these two examples, many markers might be shared between
various cancer types as seen on cell lines and on tumorous and
non-tumorous tissues making the differentiation extremely chal-
lenging. Even a highly sophisticated methodology as MV protein
typing could confirm the presence of cancer but not its differen-
tiation despite the fact that this profiling at least could identify
therapy responder (30).
While these approaches were not as promising as hoped to
pinpoint the cancer entities, the discovery of highly sensitive and
specific “pan-cancer-MV/MP” marker could be usable to screen
for cancer outbreak, especially, when the conventional differential
diagnostic tools would not yet indicate the presence of the tumor
or to overcome limitations of certain diagnostic methodologies
such as biopsies or X-ray imaging if frequently applied.
Thus, a specific EV surface antigen combination unique for an
individual cancer entity and differing from other cancer derived
EVs is due to be explored but apparently not yet identified leading
to the likely pre-matured conclusion that such EV surface com-
bination might not exist. In the past decade, EpCAM (CD326)
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Table 1 | Summary of the MP/MV profiles of indicated diseases and used surface MP/MV markers.
Disease MP/MV parental cell MP/MV surface markers Sample kind Reference
Meningococcal sepsis CD4 T-Lymphocytes Annexin V+CD4 Plasma (28)
CD8 T-Lymphocytes Annexin V+CD8
Monocytes Annexin V+CD14
B-Lymphocytes Annexin V+CD20
Platelets Annexin V+CD61
Endothelial cells Annexin V+CD62e
Granulocytes Annexin V+CD66b
Erythrocytes Annexin V+Glycophorin A
Atherosclerosis CD4 T-Lymphocytes Annexin V+CD4 Atherosclerotic
plaques
(29)
Monocytes Annexin V+CD14
Granulocytes Annexin V+CD66b
Endothelial cells Annexin V+CD144
Red blood cells Annexin V+CD235a
Dermatomyositis T-Lymphocytes Annexin V+CD3 Plasma (21)
Monocytes/Macrophages Annexin V+CD14
B-Lymphocytes Annexin V+CD19
Arthritis T-Lymphocytes Annexin V+CD3 Synovial fluid (17)
Monocytes/Macrophages Annexin V+CD14
Neutrophils Annexin V+CD15
Platelets Annexin V+CD41
Malaria T-Lymphocytes Annexin V+CD3 Plasma (19)
Monocytes Annexin V+CD11b
Platelets Annexin V+CD41
Endothelial cells Annexin V+CD105+CD51
Red blood cells Annexin V+CD235a
Chronic hepatitis C CD4 T-Lymphocytes Annexin V+CD3 Serum (6)
CD4 T-Lymphocytes Annexin V+CD4
CD8 T-Lymphocytes Annexin V+CD8
Monocytes Annexin V+CD14
Neutrophils Annexin V+CD15
Platelets Annexin V+CD41
Chronic hepatitis C vs. non-alcoholic
steatohepatitis
CD4 T-Lymphocytes Annexin V+CD4 Serum (12)
CD8 T-Lymphocytes Annexin V+CD8
Monocytes Annexin V+CD14
Neutrophils Annexin V+CD15
Platelets Annexin V+CD41
iNKT cells Annexin V+Valpha24/Vbeta11
turned out to be a useful marker to detect circulating tumor cells
(CTCs) or tumor stem cells (44–47). Although they are rare, the
optical detection of such EpCAM+ tumor cells as done with the
CellSearch™ system is in clinical use for a limited number of can-
cer entities (44, 48, 49). This method depends on metastatic spread
of tumor cells from the primary tumor side and free float of tumor
cells in the circulation (49). In contrast to these scarce CTCs,
EpCAM+ EVs might be larger in numbers, a possible multiplier in
fact of EpCAM+ tumor cells in vivo. More importantly, EV shed-
ding is not depending on metastatic spread rather than activation
and apoptosis. Thus, these tumor EVs might reach the circulation
(50) as CTCs and being not restricted to metastatic tumor spread
(51). Fairly, it must be taken into account that non-tumorous cells
shed potentially EpCAM+ EVs making discrimination between
tumorous and non-tumorous EVs difficult.
miRNA CARRYING CANCER DERIVED EVs
Another promising methodology of detecting and identifying
tumor entities is currently the screening for extracellular miRNA.
Some milestones were achieved as reviewed and summarized by
others (52, 53). These studies gave rise to the hypothesis that
miRNA packed in EVs as detectable in body fluids might serve
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FIGURE 1 | Workflow of current MP/MV profiling strategies. From less
than 10 mL of blood sample first serum is prepared and subsequently MPs
are isolated using ultracentrifugation and Annexin V enrichment. The
isolation is followed by either a miRNA analysis of MP/MV content or FACS
phenotyping using various surface marker combinations determining the
underlying disease. The MP/MV profile generated this way could help
health screening, diagnosis, and tumor differentiation.
as a promising biomarker for various pathological conditions (53)
including prostate cancer (54) and glioblastoma multiform (29)
or to monitor pathological changes of biological processes regu-
lated by miRNA (55). Going in line with these observations and
suggestions, it has recently been shown that these miRNA and
mRNA detected within the EV lumen potentially participate in
modulating the tumor niche by enhancing angiogenesis (56) and
endothelial cell proliferation in vitro (57). Another work high-
lighted that muscle loss during cancer development might be
attributed to miRNA packed in EVs (58).
Of note, combining miRNA arraying of MP content together
with the surveillance of specific tumor derived EVs, might offer
a novel opportunity to overcome the above discussed limitations
due to overlapping surface markers as seen for tumor derived EVs
forging a clear differentiation among tumor entities nearly impos-
sible. So far, several interesting experimental attempts acknowl-
edged the idea to isolate and screen tumor derived EV miRNA.
Promisingly, Sun et al. demonstrated that the combination of EV
isolation and EV miRNA arraying might be feasible as a new type
of combined tumor biomarker (59). Noteworthy, they used crude
MV preparation, without the enrichment for Annexin V posi-
tive MVs or for other known MV populations positive for any of
the previously discussed cancer markers such as EpCAM. Nev-
ertheless, their presented data convincingly demonstrated that
miRNAs were differentially expressed in MVs originating from
HCC patients compared with chronic hepatitis B and normal
control cohorts (59). Another interesting publication that could
distinguish between healthy and cancer patients used a similar
methodology, isolation of crude EVs and EV miRNA array, for
cholangiocarcinoma (CCA) diagnosis (60).
In both trials, miRNA differences were explored in samples
of tumor free cohorts vs. tumor samples of known cancer enti-
ties raising the question if this approach can distinguish between
unknown tumor entities as well. Therefore, the combination of
EV profiling and FACS based sorting or magnetic beads based
enrichment of these potentially tumor derived EVs with miRNA
screening might enable scientist to address two main questions: is
a tumor present and if so what kind/entity does the tumor has. For
example, EpCAM+ EVs together with miRNA array could serve as
such tool in the future.
CONCLUSION
Nevertheless, the incline of tumor derived EVs or miRNA levels
detectable in these circulating EVs in patients at risk with a high
probability to develop cancer might provide a novel tool with a
huge clinical potential and impact. If reliable and proven cut off
values with useful positive predictive values for tumor derived or
disease associated EV profiles can be achieved, the MP profile could
pinpoint the underlying tumor or disease entity and even it could
overcome sample variability as often seen in case of biopsies. This
could be combined with screening for tumor EVs packed with a
specific set of miRNA as discussed above. This way, not only the
disorder entity could be revealed, but treatment outcome could
be monitored separating responders from non-responders by one
minimally invasive blood sampling. Disease registers, containing
standardized sets of disease signatures of EV surface markers, and
other associated and standardized disease parameters, might be
very well the future. But until that several questions are remained
and need to be addressed. Specifically, larger studies are necessary,
providing evidence that the differentiation among disease enti-
ties is reliably and consistently feasible. Additionally, larger panel
of surface markers and thereby MP/MV populations need to be
measured in a comprehensive manner during the various diseases.
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Certainly, the ultimate goal should remain: the early detection of
various chronic diseases especially cancer and the distinguishing
of cancer entities.
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